下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEK-604dihydrochlorideCat.No.:HY-100400ACASNo.:217094-32-1分?式:C??H??Cl?N?OS?分?量:575.64作?靶點(diǎn):Acyltransferase作?通路:MetabolicEnzyme/Protease儲(chǔ)存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed
storage,awayfrommoisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:100mg/mL(173.72mM;Needultrasonic)DMSO:62.5mg/mL(108.57mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.7372mL8.6860mL17.3720mL5mM0.3474mL1.7372mL3.4744mL10mM0.1737mL0.8686mL1.7372mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;?旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限:-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.25mg/mL(3.91mM);Clearsolution2.請(qǐng)依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.25mg/mL(3.91mM);Clearsolution3.請(qǐng)依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.25mg/mL(3.91mM);Clearsolution4.請(qǐng)依序添加每種溶劑:PBSSolubility:100mg/mL(173.72mM);Clearsolution;Needultrasonicandwarmingandheatto60°CBIOLOGICALACTIVITY?物活性K-604dihydrochloride?種有效的選擇性酰輔酶A:膽醇酰轉(zhuǎn)移酶1(ACAT-1)抑制劑,IC50為0.45±0.06μM。IC50&TargetACAT-1ACAT-20.45μM(IC50)102.85μM(IC50)體外研究ThepotencyandselectivityofK-604forhumanACAT-1andACAT-2isexamined.TheIC50valueofK-604forhumanACAT-1is0.45μMandthatforhumanACAT-2is102.85μM,indicatingthatK-604is229-foldmoreselectiveforACAT-1thanACAT-2.Kineticanalysisindicatesthattheinhibitioniscompetitivewithrespecttooleoyl-coenzymeAwithaKivalueof0.378μM.K-604efficientlyinhibitscholesterolesterificationinhumanmacrophageswithIC50valueof68nM[1].Incellfreebiochemicalassays,K604at0.5μMinhibitsACAT1enzymaticactivityby70%withoutsignificantlyinhibitingtheACAT2enzymeactivity.ToinvestigatewhetherblockingACAT1increasesautophagyinneuronalcells,N2acellsaretreatedwithK604.Theresultshowsthatat0.1to1μM,K604inhibitsACATactivityby60-80%.NextK604isaddedtoN2acellsatconcentrationsfrom0.1to1μMfor24h,andLC3levelsareexaminedbywesternblot.TheresultshowsthatK604increasestheLC3-II/LC3-Iratio,areliablemarkerforautophagosomeformation,inadose-dependentmanner.ThenumberofthefluorescentLC3punctaissignificantlyincreasedinN2acellsafterK604treatment.Bywesternblot,K604significantlydecreasesthelevelsofp62inN2acells[2].體內(nèi)研究UsingF1Bhamsters,ananimalmodelsusceptibletodiet-inducedhyperlipidemiaandatherosclerosis,theeffectsofK-604onaorticlesionareasandplasmacholesterollevelsareassessed.AdministrationofK-604doesnotaffectbodyweightorfoodconsumption.Theplasmacholesterollevelsinfat-fedhamstersare~12-foldhigherthanthoseinchow-fedhamsters,whicharesignificantlydecreasedbyK-604onlyatthehighestdosetested(30mg/kg)butnotatlowerdoses(1-10mg/kg).ThefattystreaklesionsstainwithoilredOaremarkedlyinducedbythehigh-fatdiet,whichissignificantlyreducedbyadministrationofK-604.Further,thehistologicalanalysesoftheatheroscleroticlesionsareperformed.Thefattystreaklesionsinthecontrolgrouparecharacterizedbyaccumulationoffoamymacrophagesinthesubendothelialspace.Incontrast,theareasoccupiedbyfoamymacrophagesaremarkedlyreducedbyadministrationofK-604[1].PROTOCOLKinaseAssay[1]ACATactivityisdeterminedbymeasuringtheproductionofcholesteryl[14C]oleate.MicrosomalfractionsderivedfromCHO-ACAT-1orCHO-ACAT-2cellsaredilutedwithCHAPSin0.5MKCl,0.5mMEDTA,and25mMTris-HCl(pH7.8)(bufferA)toafinalproteinconcentrationof1.0mg/mL.Themicrosomalfractions2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEcontaining9.2μgofproteinforACAT-1or4.9μgforACAT-2in10μLofbufferAaremixedwithvariousconcentrationsofK-604(0.4,0.6and0.8μM)orCI-1011in5μLofDMSO,andreconstitutedwith152.5μLofmixedmicellescontaining1.6mMCholesterol,11.2mMPhosphatidylcholine,and9.3mMTaurocholatein25,0.5mMEDTA,andTris-HCl(pH7.8).Thereactionisstartedbyadding10μLof0.45μM[14C]oleoyl-CoA,10nMfattyacid-freebovineserumalbumin(fattyacid-freeBSA)and25mMTris-HCl(pH7.8).Reactionmixturesareincubatedfor25minat37°Candterminatedbyadding150μLofChloroform/Methanol(2:1).Theorganicphaseisdriedunderastreamofnitrogen.Thelipidsareresuspendedwith150μLofChloroform/Methanol(2:1)anddevelopedbythinlayerchromatography(TLC)usinghexane/diethylether/aceticacid(75:25:1).Radioactivitiesofcholesterol[14C]oleatearedeterminedusingaBAS2500imageanalyzer[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.CellAssay[2]ThemouseneuroblastomacelllineN2aisculturedinDMEM/Opti-MEM(50:50)with10%fetalbovineserum(FBS)at37°Cwith5%CO2inahumidifiedincubator.Cellsareincubatedfor24hwiththeACAT1-specificinhibitorK604(0.1,0.5and1μM)orisotype-nonspecificACATinhibitorCI-1011.Primarycorticalneuronsareisolatedfrommousebrainsatpostnatalday0-3.Corticalneuronsareplatedin6wellplatesat350,000cells/wellandgrownin2mL/wellNeurobasalAwith1×B27,0.5mML-glutamine,and5ng/mLfibroblastgrowthfactor.Halfofthemediaisreplacedwithfreshmediaonceevery7days.After14-21daysinculture,cellsareusedforindividualexperiments[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalHamsters[1]Administration[1]MaleF1Bhamsters(n=30)at8weeksoldareusedforanimalexperiments.Theanimalroomiscontrolledat23±3°Candrelativehumidityof50±20%.AnimalsarefedaCE-2chowdiet,followedbysupplementationwithCE-2containing0.3%cholesteroland10%coconutoilfor10weeks.Duringfatloading,K-604isadministeredorallyat1,3,10,or30mg/kg/day(n=6foreachdosegroup).Thecontrolgroup(n=6)receiveanaqueoussolutionof0.5%methylcelluloseinsteadofK-604.Tapwaterisgivenadlibitum.Bodyweightismeasuredatthetimeofdrugadministration.Bloodissampledfordeterminationofplasmacholesterollevelsusingacommerciallyavailablekit(CholesterolE-Test).MCEhasnotindependentlyconf
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- PB-22-8-Hydroxyisoquinoline-isomer-生命科學(xué)試劑-MCE-5052
- Lariciresinol-4-O-β-D-glucopyranoside-生命科學(xué)試劑-MCE-5846
- E3-Ligase-Ligand-linker-Conjugate-122-生命科學(xué)試劑-MCE-1944
- 二零二五年度航空航天產(chǎn)業(yè)融資合作協(xié)議書(shū)
- 二零二五年度用人單位與派遣公司國(guó)際化人才派遣服務(wù)協(xié)議
- 2025年度音樂(lè)制作與音樂(lè)版權(quán)許可合同
- 2025年度活動(dòng)板房銷(xiāo)售與臨時(shí)辦公場(chǎng)所租賃合同
- 二零二五年度商業(yè)地產(chǎn)貸款合同范本
- 2025年度飯店短期餐飲服務(wù)員勞務(wù)派遣協(xié)議
- 二零二五年度工業(yè)用地使用權(quán)整體轉(zhuǎn)讓合同
- 2025年廣州中醫(yī)藥大學(xué)順德醫(yī)院(佛山市順德區(qū)中醫(yī)院)招考聘用高頻重點(diǎn)提升(共500題)附帶答案詳解
- 2025年華僑港澳臺(tái)學(xué)生聯(lián)招考試英語(yǔ)試卷試題(含答案詳解)
- 2025-2030年中國(guó)美容院行業(yè)營(yíng)銷(xiāo)創(chuàng)新戰(zhàn)略制定與實(shí)施研究報(bào)告
- 2024-2025學(xué)年北京石景山區(qū)九年級(jí)初三(上)期末語(yǔ)文試卷(含答案)
- 第一章 整式的乘除 單元測(cè)試(含答案) 2024-2025學(xué)年北師大版數(shù)學(xué)七年級(jí)下冊(cè)
- 藥品流通監(jiān)管培訓(xùn)
- JD37-009-2024 山東省存量更新片區(qū)城市設(shè)計(jì)編制技術(shù)導(dǎo)則
- 中國(guó)高血壓防治指南(2024年修訂版)
- 北京市海淀區(qū)重點(diǎn)中學(xué)2025屆高考數(shù)學(xué)押題試卷含解析
- 2024EPC施工總包合同范本
- GB/Z 44765.3-2024用戶端能源管理系統(tǒng)和電網(wǎng)側(cè)管理系統(tǒng)間的接口第3部分:架構(gòu)
評(píng)論
0/150
提交評(píng)論